These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 22068471)

  • 1. [Recent Advances in α-dystroglycanopathy].
    Kuga A; Kanagawa M; Toda T
    Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
    Toda T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review.
    Taniguchi-Ikeda M; Morioka I; Iijima K; Toda T
    Mol Aspects Med; 2016 Oct; 51():115-24. PubMed ID: 27421908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan.
    Godfrey C; Clement E; Mein R; Brockington M; Smith J; Talim B; Straub V; Robb S; Quinlivan R; Feng L; Jimenez-Mallebrera C; Mercuri E; Manzur AY; Kinali M; Torelli S; Brown SC; Sewry CA; Bushby K; Topaloglu H; North K; Abbs S; Muntoni F
    Brain; 2007 Oct; 130(Pt 10):2725-35. PubMed ID: 17878207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.
    Kuwabara N; Manya H; Yamada T; Tateno H; Kanagawa M; Kobayashi K; Akasaka-Manya K; Hirose Y; Mizuno M; Ikeguchi M; Toda T; Hirabayashi J; Senda T; Endo T; Kato R
    Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9280-5. PubMed ID: 27493216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
    Toda T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan.
    Kuga A; Kanagawa M; Sudo A; Chan YM; Tajiri M; Manya H; Kikkawa Y; Nomizu M; Kobayashi K; Endo T; Lu QL; Wada Y; Toda T
    J Biol Chem; 2012 Mar; 287(12):9560-7. PubMed ID: 22270369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosylation with ribitol-phosphate in mammals: New insights into the O-mannosyl glycan.
    Manya H; Endo T
    Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2462-2472. PubMed ID: 28711406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and localization of fukutin, POMGnT1, and POMT1 in the central nervous system: consideration for functions of fukutin.
    Yamamoto T; Kato Y; Kawaguchi M; Shibata N; Kobayashi M
    Med Electron Microsc; 2004 Dec; 37(4):200-7. PubMed ID: 15614444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
    Ohtsuka Y; Kanagawa M; Yu CC; Ito C; Chiyo T; Kobayashi K; Okada T; Takeda S; Toda T
    Sci Rep; 2015 Feb; 5():8316. PubMed ID: 25661440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fukuyama-type congenital muscular dystrophy (FCMD) and alpha-dystroglycanopathy.
    Toda T; Kobayashi K; Takeda S; Sasaki J; Kurahashi H; Kano H; Tachikawa M; Wang F; Nagai Y; Taniguchi K; Taniguchi M; Sunada Y; Terashima T; Endo T; Matsumura K
    Congenit Anom (Kyoto); 2003 Jun; 43(2):97-104. PubMed ID: 12893968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.
    Xiong H; Kobayashi K; Tachikawa M; Manya H; Takeda S; Chiyonobu T; Fujikake N; Wang F; Nishimoto A; Morris GE; Nagai Y; Kanagawa M; Endo T; Toda T
    Biochem Biophys Res Commun; 2006 Dec; 350(4):935-41. PubMed ID: 17034757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fukutin and alpha-dystroglycanopathies.
    Toda T; Chiyonobu T; Xiong H; Tachikawa M; Kobayashi K; Manya H; Takeda S; Taniguchi M; Kurahashi H; Endo T
    Acta Myol; 2005 Oct; 24(2):60-3. PubMed ID: 16550916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome.
    Beltrán-Valero de Bernabé D; Currier S; Steinbrecher A; Celli J; van Beusekom E; van der Zwaag B; Kayserili H; Merlini L; Chitayat D; Dobyns WB; Cormand B; Lehesjoki AE; Cruces J; Voit T; Walsh CA; van Bokhoven H; Brunner HG
    Am J Hum Genet; 2002 Nov; 71(5):1033-43. PubMed ID: 12369018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fukutin mutations in non-Japanese patients with congenital muscular dystrophy: less severe mutations predominate in patients with a non-Walker-Warburg phenotype.
    Yis U; Uyanik G; Heck PB; Smitka M; Nobel H; Ebinger F; Dirik E; Feng L; Kurul SH; Brocke K; Unalp A; Özer E; Cakmakci H; Sewry C; Cirak S; Muntoni F; Hehr U; Morris-Rosendahl DJ
    Neuromuscul Disord; 2011 Jan; 21(1):20-30. PubMed ID: 20961758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Congenital muscular dystrophy and alpha-dystroglycanopathy].
    Saito F; Matsumura K; Hagiwara H; Shimizu T
    Rinsho Shinkeigaku; 2008 Aug; 48(8):543-9. PubMed ID: 18939472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Missense mutations in β-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome.
    Buysse K; Riemersma M; Powell G; van Reeuwijk J; Chitayat D; Roscioli T; Kamsteeg EJ; van den Elzen C; van Beusekom E; Blaser S; Babul-Hirji R; Halliday W; Wright GJ; Stemple DL; Lin YY; Lefeber DJ; van Bokhoven H
    Hum Mol Genet; 2013 May; 22(9):1746-54. PubMed ID: 23359570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent advances in congenital muscular dystrophy research].
    Nonaka I
    No To Hattatsu; 2005 Mar; 37(2):115-21. PubMed ID: 15773323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosylation defects: a new mechanism for muscular dystrophy?
    Grewal PK; Hewitt JE
    Hum Mol Genet; 2003 Oct; 12 Spec No 2():R259-64. PubMed ID: 12925572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.